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Abstract: There is a widening recognition that cancer cells are products of complex developmental 
processes. Carcinogenesis and metastasis formation are increasingly described as systems-level, network 
phenomena. Here we propose that malignant transformation is a two-phase process, where an initial 
increase of system plasticity is followed by a decrease of plasticity at late stages of carcinogenesis as a 
model of cellular learning. We describe the hallmarks of increased system plasticity of early, tumor 
initiating cells, such as increased noise, entropy, conformational and phenotypic plasticity, physical 
deformability, cell heterogeneity and network rearrangements. Finally, we argue that the large structural 
changes of molecular networks during cancer development necessitate a rather different targeting strategy 
in early and late phase of carcinogenesis. Plastic networks of early phase cancer development need a central 
hit, while rigid networks of late stage primary tumors or established metastases should be attacked by the 
network influence strategy, such as by edgetic, multi-target, or allo-network drugs. Cancer stem cells need 
special diagnosis and targeting, since their dormant and rapidly proliferating forms may have more rigid, or 
more plastic networks, respectively. The extremely high ability to change their rigidity/plasticity may be a 
key differentiating hallmark of cancer stem cells. The application of early stage-optimized anti-cancer 
drugs to late-stage patients may be a reason of many failures in anti-cancer therapies. Our hypotheses 
presented here underlie the need for patient-specific multi-target therapies applying the correct ratio of 
central hits and network influences — in an optimized sequence. 
 
Key words: adaptation; anti-cancer therapies; cancer attractors; cancer development; epithelial-mesenchymal transition; interactome; 
networks; signaling Abbreviations: BRAF, B-Raf protein; BRD4, bromodomain-containing protein 4; CDK6, cyclin-dependent kinase 6; 
ERBB1, epidermal growth factor receptor; ERG, ETS-family oncogenic transcription factor; ERK, extracellular signal regulated protein 
kinase; FOS, FBJ murine osteosarcoma viral oncogene homolog; FOXO3A, forkhead family transcription factor; IRS1, insulin receptor 
substrate 1; MMP2, matrix metalloproteinase 2; mTORC1, mammalian target of rapamycin complex 1; MYC, myelocytomatosis viral 
oncogene homolog protein; NES, nestin intermediate filament protein; p53, TP53 tumor suppressor protein; PDGFR, platelet-derived growth 
factor receptor; PI3K, phosphatidyl-inositol-3'-kinase; PKM2, pyruvate kinase M2 isoform; RAS, small GTPase protein; RHOA, RAS-
homolog gene family member A; TGFBR, Transforming growth factor-β receptor; TNC, tenascin C protein. 
 
In this paper first we will describe cancer development as a two-phase phenomenon characterized by a 
first increased than decreased plasticity (or in alternative wording: by a first decreasing than increasing 
rigidity) at the systems-level. We will propose that cancer stem cells have the unique property to 
induce rapid and gross changes of their network plasticity/rigidity. Next, we will list the cancer-
specific properties of molecular networks highlighting the adaptation of network structure and 
dynamics in various stages of cancer development as a model of cellular learning. Finally, we will 
highlight that different network-related anti-cancer strategies are needed to target early and late stage 
cancer cells, as well as cancer stem cells, and will list the possibilities to target all these cell 
communities. 
 
1. Development of cancer as a learning process of increasing and then decreasing plasticity at the 
systems-level 
 
Cancer cells are products of a complex cell transformation process. The starting steps of this process 
are often mutations or DNA-rearrangements, which destabilize the former cellular phenotype. As a 
result, a cell population with a large variability in  
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hromatin organization (including DNA-hypomethylation, histone
odification and chromatin structure), gene expression patterns
nd interactome composition is formed. This heterogeneous cell
opulation is characterized by an increased level of stochastic pro-
esses (noise), phenotypic plasticity [1–6], and by an increase in
he network entropy of protein-protein interaction networks (the
efinitions of local and more global variants of network entropy see
n [7–9]). Higher degree-entropy of signaling networks was  found
o correlate with lower survival of prostate cancer patients [9],
hich underlies both the medical relevance and the generality of
hese changes. Increased heterogeneity may  help survival not only
t the level of individual cells, but also by allowing the formation
f cooperating inter-cellular networks of cancer cells [10,11]. This
ooperative, paracrine cross-regulation may  change to a selfish,
utocrine development later [12,13].
In many general aspects, the development of cancer cells resem-
les to that resulting in changes of cellular phenotypes e.g. during
mbryogenesis. Major steps of the epithelial-mesenchymal transi-
ion (where epithelial cells lose both their apical/basal polarity and
riginal cellular contacts, gain the ability to transverse the extra-
ellular matrix, and ultimately contribute to tissues other than the
riginal epithelial sheet) correspond well to the major stages of
etastasis formation [14,15].
Here we argue that malignant transformation is essentially a
wo-phase process. We  propose that the first phase of malignant
ransformation is characterized by an increase of plasticity in the
rotein-protein interaction, signaling and other networks of trans-
ormed cells, which is followed by decrease of network plasticity
Fig. 1), where network plasticity (or in other words network flex-
bility) is related to the degrees of freedom of network nodes [16].
he initial stage may  correspond to “clonal expansion”, and the
ppearance of tumor initiating cells. The late stage may  represent
ither late-stage primary tumor cells, or metastatic cells, which
lready settled in their novel tissue environment.
Cancer stem cells [17] can possess both types of the above dual-
ty. Cancer stem cells can display a dormant phenotype, which
s not rapidly proliferating, and has a more rigid structure of its
rotein-protein interaction, signaling and other networks than that
f rapidly proliferating early stage tumor cells. Importantly, cancer
tem cells may  also possess a rapidly proliferating phenotype [17],
hich may  have a highly plastic network structure. Therefore, can-
er stem cells are not discriminated by the plasticity of their actual
etwork structures (called as structural plasticity [16]), but by their
specially high ability to modulate the plasticity of their networks
called as dynamic plasticity [16]) according to the needs of the
nvironment. It is important to note that the specially high ability
f cancer stem cells to modulate the plasticity of their networks is in
ccordance with the original cancer stem cell definition of tumor
nitiation after serial dilutions [17]. A highly increased ability of
lasticity modulation (which results in an increased level of evol-
ability) may  prove to be a major discriminatory hallmark of cancer
tem cells. Importantly, this increased plasticity modulation ability
ay  be a key reason why anti-cancer therapies often induce cancer
tem cells instead of killing or transforming them.
There are many signs of the initial increase of system plasticity
uring cancer development, such as the increased heterogeneity,
oise and entropy mentioned before. Tumor initiating cells showed
 larger plasticity also at the level of physical deformability [18,19].
owever, at late stage carcinogenesis of the primary tumor, or
hen tumor cells already established metastases and were incor-
orated to a more stable tissue environment, the systems-level
lasticity of cancer cells may  decrease again.The cancer-specific, metastable states, which were termed as
cancer attractors” by Stuart Kauffman in 1971 [3,20] may  be
specially typical to these later stages of cancer development. Addi-
ionally, early stages of cancer development may  be characterizeder Biology 23 (2013) 262– 269 263
by numerous “shallow” cancer attractors developing a more plastic
structural network of the cell residing in transit on this relatively
smooth state space environment, while late stages of tumor devel-
opment may  involve fewer but “deeper” cancer attractors, where
the cancer cell becomes stabilized in this more rough state space
environment. The dual change described above corresponds well
to various steps in the transition to cancer attractors, since cancer
cells should first cross a barrier in the (epigenetic) fitness land-
scape, which might be lowered by mutations or epigenetic changes
[3], but still requires a transient destabilization of the transforming
cell, which leads to a more plastic phenotype with all the pheno-
typic characteristics described before. The phenotype of the already
established, late-stage cancer cells is still more plastic and imma-
ture than that of normal cells, but may  often be more rigid than the
phenotype of the cells in the intermediate stages of carcinogenesis
(Fig. 1).
Such a biphasic change resembles to that of cell differentiation
processes, where an initial increase of entropy of chromosomal
order and co-regulated gene expression pattern is followed by a
later decrease [21]. An analogous set of events happens in cel-
lular reprogramming, where single-cell studies revealed that an
early stage, very heterogeneous, stochastic phase is followed by a
late phase, which is programmed by a hierarchical set of transcrip-
tion factors [22]. The recently discovered super-enhancers [23,24]
may  characterize this second, consolidated phase of phenotype
rearrangement. Importantly, a more ordered system is generally
less controllable than a disordered one [25], which warns that (A)
therapeutic interventions of early stage of carcinogenesis are more
efficient than those against late-stage tumors; (B) late-stage tumors
should be attacked by a fully different strategy than early-stage
tumors preferring indirect targets having a smaller centrality in
molecular networks, which cause less side effects and toxicity in
these more rigid, late-stage cancer-specific networks/cellular sys-
tems, see Fig. 1 and [26].
2. Network segments participating in adaptive processes
The cancer development process is increasingly described
as a systems-level, network phenomenon [27,28]. Applying this
description to the cancer development stages described above, in
this section we  summarize the adaptation options of network struc-
tures in general. In Section 3, we  will describe the cancer-specific
network adaptation events.
Adaptation of networks is often described as “network evolu-
tion”, where the term refers to changes in the network contact
structure (e.g. changes of parameters like network connectivity,
edge weights, diameter, centrality, motifs or modules [29,30]). The
identification of these changes has a predictive potential both in
retrospect and about future development of the complex system
represented by the network. Network evolution may  follow dif-
ferent timescales varying from microseconds to decades or more
[31–33]. Thus the assessment of molecular network changes in
the progression of cancer requires a very careful selection of time-
frames both in clinical sampling and in network analysis.
Network dynamics extends the frame of network evolution to
the refined changes of network nodes (e.g. individual proteins)
when transmitting signals, or participating in their cellular func-
tion requiring a concerted action of multiple proteins. Network
dynamics is strongly related to the underlying network topology.
Transitions to a new state, as it was seen in tumor development
[34], have key importance in network dynamics.Hubs (i.e. nodes with much more neighbors than the average)
are key determinants of local network topology [35]. A key example
of these highly connected hubs is the p53 protein. The p53 tumor
suppressor is indeed a key regulator of cancer-related molecular
264 D.M. Gyurkó et al. / Seminars in Cancer Biology 23 (2013) 262– 269
Fig. 1. Development of cancer as a learning process of increasing and then decreasing plasticity at the systems-level determines the most appropriate drug targeting strategy.
The  figure illustrates the major hypothesis of the current review showing that the transition of cells to a cancer attractor during malignant transformation is essentially
a  two-phase process. We  propose that in this transformation an initial increase of system plasticity is followed by a late-stage decrease of plasticity. Plastic, early stage
systems  of cancer development are characterized by a higher level noise, entropy and physical deformability. The plastic → rigid transition of network structure during
cancer  development invokes a rather different targeting strategy in early and late phase of carcinogenesis. While at the early phase of cancer development hitting of central
nodes  (such as hubs, marked as “1”; inter-modular bridges, marked as “2”; or bottlenecks, marked as “3”) being in the cross-roads of regulatory processes may  be a winning
strategy, at later stages of carcinogenesis the more indirect means of network influence strategy, such as the multi-target (marked as “4”), edgetic (marked as “5”) or allo-
network drugs (marked as “6”) [26,79,80] should be used. Importantly, heterogeneous cancer cell populations [6,92] may harbor early- and late-stage tumor cells at the same
time.  Moreover, cancer stem cells [16] may  have the ability to change their “plasticity phenotype” from that of early- to late-stage tumor cells and vice versa. Therefore,
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etworks [36–38]. Many different pathways may  converge on hubs,
hich are often evolutionary conserved proteins [39]. Reversely, a
ub often acts as a distributor of perturbations. Network motifs are
epeated local patterns of network topology typically consisting of
 to 6 nodes. Negative feedback loops and feed-forward loops are
ignificant motifs in adaptation [40,41].
Network modules are groups of nodes connected more densely
o each other than to the rest of the network. In molecular
etworks a spatial or temporal module often means a functional
nit [42]. Altered modularity was shown as a predictive mea-
ure in breast cancer prognosis [43]. Most modules of cellular
etworks have a high overlap with each other [44,45]. Modules
f the yeast protein–protein interaction network are becoming
ore condensed and displaying smaller overlaps upon stress [46].
n extreme cases stress may  result in the disintegration of the
etwork leading to the death of the organism, which may  be an
mportant part of the network-level mechanism of action of several
nti-cancer drugs.
Modules may  segregate network segments, which are more
lastic and/or more rigid. While rigid network segments preserve
he result of a past adaptive process often displaying an optimized
unction, flexible network segments are capable of plastic adapta-
ion to present or future challenges of the environment. While rigid
etwork segments are able for fast signal transmission without a
arge dissipation, plastic network segments have a slower signal
ransmission and a larger dissipation [16,26,47].
Bridges are node-pairs connecting modules, and a bottleneck is
 key inter-modular node. Network perturbations have to propa-
ate through these nodes, therefore bridges and bottlenecks are
mportant points of regulation and adaptation [48,49]. The so-
alled creative nodes [50] are joining multiple modules in a highly
ynamic fashion. Creative nodes connect functionally distinct mod-
les. Therefore, the abundance of these exceptionally unpredictable
odes may  be a key regulator of “adaptation-speed” and related sys-
em plasticity and evolvability. Fig. 2 illustrates the most important
tructural elements of network adaptation. influence-type drugs may  provide an even more useful anti-cancer therapeutic
3. Cancer-specific properties of molecular networks
After the description of key network segments participating
in adaptive processes in general, here we  summarize the current
knowledge on the most important changes of molecular networks
in cancer development. Table 1 highlights a few proteins playing a
key role in cancer-related molecular networks.
Protein structure networks have nodes of proteins as amino
acids, where the edge weight depends on the distance of two  neigh-
boring amino acids in the 3D structure of the protein. Detailed
studies on the network representation of cancer-specific pro-
teins and their mutations are missing. However, recurrent findings
showed that intrinsically disordered proteins play an important
role in cancer-specific cellular events [51–53]. Additionally, cancer-
related proteins have smaller, more planar, more charged and
less hydrophobic binding interfaces than other proteins, which
may  indicate a low affinity and high specificity of cancer-related
interactions [54]. An increased “conformational noise” in can-
cer represented by intrinsically disordered proteins and by low
affinity interactions would be in agreement with the more plas-
tic network structure of tumor initiating cells. Our hypothesis
would predict a decreased expression of disordered proteins or
proteins with low affinity interactions in the late-phase of can-
cer development (i.e. in late stage primary tumors, or when
metastatic cells already settled in the novel tissue environment)
as opposed to the early phases of “clonal expansion”, or cancer
stem cell formation, where the expression of these proteins may
be higher.
Protein–protein interaction networks (interactomes) have the
individual proteins (or their domains) as nodes, and their phys-
ical interactions as edges. Cancer-specific interactomes may be
constructed by taking into account protein abundances, or (as
a first approximation) incorporating mRNA expression patterns
[48,55,56]. A microarray gene profiling study showed that genes
with elevated expression are coding well-connected proteins,
while suppressed genes code less connected proteins in lung
D.M. Gyurkó et al. / Seminars in Cancer Biology 23 (2013) 262– 269 265
Fig. 2. Examples of key structural segments participating in network adaptation. The figure illustrates a few key structural network segments, which often play a key role in
the  adaptation of complex systems. Intra-modular hubs are highly connected, central nodes collecting and distributing network perturbations. Bridges and bottlenecks are
crucial  regulators of information flow between network modules. Network modules often functional units and may  display a rigid or flexible structure. While the former has
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Neen  optimized to a certain function, and may  serve as a “memory” of the network
lasticity promoting adaptive processes in the present or future.
quamous cancer [57]. Interactome-based studies indicated that
roteins with cancer-specific mutations are hubs with a tendency
o form a “rich-club”, i.e. being connected with each other [58],
nd are located in the center of modules or create bridges between
hem [59]. Inter-modular hubs, such as IRS1 or BRAF, have a partic-
larly important role in oncogenesis [43]. Cancer-related proteins
end to form transient interactions and usually involved in mul-
iple pathways [54]. Dynamical rearrangements of interactome
egments may  contribute to the changes in plasticity during cancer
evelopment. Gene-expression enriched protein–protein interac-
ion networks of 6 cancer types showed an increased network
ntropy, if compared to interactomes of healthy cells [8]. Increased
etwork-entropy may  be an important ingredient of the increased
lasticity of malignant cells, and may  significantly contribute to
he increased robustness against stress and other environmental
timuli.
able 1
etwork drug target options.
Molecular network type Possible drug targets 
Protein–protein interaction network p53, CDK6 
Signaling network ERBB1
PDGFR, TGFBR
Genetic interaction network MYC, NES, MMP2, FOS, TNC 
Chromatin network BRD4 
Metabolic network Fumarate hydratase, Succinate
dehydrogenase,
PKM2rving the result of successful adaptation to past events, the latter may  provide the
The autonomy of the cancer cell is based mainly on the changes
in its signaling network, formed by interconnected signaling path-
ways including its gene regulatory network [60]. Changes in the
expression level of signaling proteins in cancer cells may  cause
the activation of major cancer-related pathways, and can rewire
the whole signaling network, as it was  shown in the case of the
epidermal growth factor receptor (ERBB1) signaling network [61].
Cross-talks between the individual signaling pathways are able to
create a high number of new input-output combinations increas-
ing the plasticity of the signaling network [2]. Earlier, we  found a
significant change in the expression level of specific cross-talking
proteins in hepatocellular carcinoma leading to a highly different,
malignant network of signaling pathways [62]. The up-regulation
and cross-talks of RAS-ERK and PI3K-mTORC1 pathways play a key
role in the progression of several tumor types [63]. The regulation of
signaling cross-talks highly depends on the spatial organization of
Cancer-specific network properties of possible drug targets References
Hub inactivation, bottleneck dysfunction [36,49]
Edgetic perturbation of receptor tyrosine kinase pathway
Cross-talks of different pathways during
epithelial-mesenchymal transition
[61]
[95]
Hub over-activation, hub-driving node under-activation [96]
Super-enhancer participating hub [23]
Targeting the Warburg effect,
Increased metabolic flux
[97]
[98]
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he cell involving differences in molecular crowding [64], scaffold
roteins [65], protein translocation [66] or membrane association
67]. Increased network entropy was found in the signaling net-
ork of the metastasizing phenotype of breast cancer, if compared
o non-metastasizing cells [7]. This may  indicate the increased
lasticity of cancer-specific signaling in the early phases of tumor
evelopment. Our recent studies showed that increased plastic-
ty of signaling networks characterizes the initial stages of tumor
evelopment (such as adenomas) better than later stages of malig-
ant transformation (such as carcinomas; Dezso˝ Módos, Katalin
enti, Tamás Korcsmáros and Péter Csermely, in preparation).
Transcriptional regulation is often executed by a hierarchical
ascade of transcriptional factors. The recently discovered super-
nhancers [23,24] showed that master transcription factors may
ften establish a cancer-specific super-enhancer locus. Whether
he organization of these super-enhancer regions represents a late-
hase of carcinogenesis, and is preceded by a very heterogeneous,
tochastic early phase, like that in cell reprogramming [22], is an
pen question of future studies.
Chromatin networks are formed by connections between dis-
ant DNA-segments, and can be used for the explanation of the
hromosomal alterations in cancer [68]. The overexpression of
he prostate cancer oncogenic transcription factor, ERG induced
 profound effect on chromatin network configuration [69]. Fur-
her studies are needed to assess the cancer-specific alterations of
ranscription-related chromatin networks, such as that describing
he connection pattern established by the active RNA-polymerase
I-complex [70].
Regulation or mutations of microRNAs play a crucial role in the
egulation of cancer-specific gene expression [71]. MicroRNAs can
unction either as tumor suppressors, such as the let-7 family mem-
ers targeting the RAS signaling pathway in breast cancer [72], or
s oncogenes, like the miR-155 targeting key breast cancer genes,
uch as FOXO3A or RHOA [73]. The analyses of cancer-specific
icroRNA networks showed more disjointed subnetworks than
n normal tissues [74]. Disjoint modules decrease the interdepen-
ence of modular changes, and also serve as an adaptive response
n stress [46]. Disjoint modules confer a greater plasticity to the
hole system.
Metabolic networks consist of major metabolites as nodes con-
ected by specific enzymatic reactions converting them to each
ther [75]. Global changes in metabolic networks contribute to the
arburg-effect, and are driven by key enzymes such as the PKM2
soenzyme of pyruvate kinase [76,77].
The stage-specific changes of molecular networks in tumori-
enesis are still largely unexplored, because we  usually have
etailed systems-level network data only on the two  endpoints,
.e. the healthy tissue and the developed late tumors. Therefore,
he assessment of consecutive changes in network structure and
ynamics during intermediate, consecutive steps of malignant cell
nd metastasis formation are key steps of future systems-level
nalysis of cancer development. Network analysis of cancer stem
ells will provide a special understanding of both plasticity modu-
ation and evolvability at the systems-level.
. Network-related anti-cancer therapies
It is a growing challenge to identify new drug targets and effi-
ient combination of drugs in order to design new anti-cancer
herapies with less toxicity, side-effects and resistance develop-
ent. As we have shown in the preceding section molecular
etworks at various levels greatly improved our systems-level
nderstanding of tumor initiation and progression [26–28,78].
Recently a dual network strategy, the central hit strategy and
he network influence strategy, was described to target variouser Biology 23 (2013) 262– 269
diseases [26]. In cancer both strategies may  be used. Using the
central hit strategy our aim is to damage the network integrity
of the malignant cell in a selective manner. This may  be the most
important strategy to attack tumor initiating cells at their first stage
of development (e.g. early stages of malignant transformation of
metastasis formation). Using the network influence strategy we
would like to shift back the malfunctioning network to its normal
state. This may be the most important way to shift back tumor cells
from their cancer attractors reached in late stages of their devel-
opment (e.g. late stage primary tumors or after the metastatic cells
settled to their new tissue environment). The central hit strategy
is applied against a population of highly destabilized cells having a
very plastic network structure. Efficient targeting of these systems
requires the targeting of their central nodes/edges. In contrast, the
network influence strategy is applied to cells, which have a much
more rigid network structure than the networks of highly undiffer-
entiated or dedifferentiated cells. Targeting the central nodes/edges
of systems having a low plasticity may  easily ‘over-saturate’ the
system causing side-effects and toxicity. Therefore, the network
influence strategy often needs an indirect approach, where e.g.
neighbors of the real target are targeted (allo-network drugs [79]).
In another indirect approach of the network influence strategy
multiple targets are targeted at the same time ‘mildly’ (using multi-
target drugs [80]), and their indirect and/or superposing effects lead
to the reconfiguration of diseased network state back to normal.
The central hit strategy often uses the key central position of
inter-modular hubs. These central nodes are often important onco-
genes serving as targets in drug development [43]. Similarly, in
signaling networks protein or microRNA hubs [48,57,58,81,82],
inter-modular positions of cross-talks [83], bottlenecks [84] as
well as multi-pathway proteins offer important target candidates
[43,62] as central hits.
However, the central hit strategy may  often attack nodes, which
are so central that their inhibition damages key functions of healthy
cells. As an example, mTOR, the mammalian target of rapamycin
is an important multi-pathway protein, which mutates in most of
the tumors and thus causes hyper-active phenotype [85]. Because
of the super-central position of mTOR, edgetic drugs targeting
single mTOR interactions have a much more selective effect [86]
than targeting all mTOR interactions by conventional drugs [87].
Another example of edgetic anti-cancer therapies is the inhibition
of p53/MDM2 connection by nutlins, which liberate the tumor-
suppressor effect of p53 from MDM2-induced inhibition [88].
The network influence strategy often implies multi-target
attacks [80]. These attacks may  allow the simultaneous targeting
of two or more peripheral nodes instead of targeting a single, cen-
tral node [25]. Such combinatorial or multi-target therapies can
be identified using interactomes, signaling or metabolic networks
[89,90] and led to the design a simultaneous targeting therapy
e.g. in colorectal cancer [91]. The systematic development of allo-
network drugs [79] acting at the neighborhood of real targets and
specifically transmitting their signals to them requires a more
detailed knowledge of both indirect targeting and the molecular
details of allosteric action, and therefore remains and major chal-
lenge of future studies.
5. Network adaptation in various stages of cancer
development as a key aspect of anti-cancer therapies
Here we  propose that the large structural changes of molecu-
lar networks during cancer development require a rather different
targeting strategy in early and late phase of carcinogenesis (Fig. 1).
While at the early phase of cancer development hitting of central
nodes in various molecular networks (such as inter-modular hubs
being in the cross-roads of regulatory processes) may  become a
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inning strategy, the very same pharmacological intervention may
ecome useless at a later stage of carcinogenesis, where the primary
umor was already established, or the metastasized cells have been
ettled in their new tissue environment. These late-stage tumor
ells should be attacked by the more indirect means of network
nfluence strategy, such as by edgetic, multi-target, or allo-network
rugs [26,79,80].
The analysis of Rajapakse et al. [25] offers important clues on tar-
eting molecular networks during cancer development. Referring
o the general observation that symmetrical networks are more
ncontrollable, they hypothesize that the highly heterogeneous,
ighly plastic, intermediate state of tumor-initiating cells right
efore or at attaining their metastatic potential is the most difficult
o attack by well-targeted external inputs. This is the phase, where
nly the central-hit strategy may  be applied. However, at late stage
rimary or metastatic tumors, where the underlying network struc-
ures became more asymmetric again (Dezso˝ Módos, Katalin Lenti,
amás Korcsmáros and Péter Csermely, in preparation) only the
ndirect effects of the network influence strategy may  be successful.
Very importantly, cancers often harbor cancer stem cells, which
ay  be induced by conventional anti-cancer therapies, themselves
16]. These stem cell-like tumor cell subpopulations possess an
xtraordinarily high ability to change their plasticity. When can-
er stem cells acquire a more dormant state, they may  change their
etworks from a more plastic to a more rigid structure. On the con-
rary, cancer stem cells may  have a transition from a more rigid to a
ore plastic network structure, if they form early tumor progenitor
ells. This large level of dynamic plasticity may  be a major reason
f the development of drug resistance in many cancer cases.
The presence of highly heterogeneous cell populations (includ-
ng various forms of cancer stem cells) in a cancer patient, as well
s the extreme heterogeneity of patient subtypes [6,92] all give a
articular importance of sequential multi-target therapies, where
ultiple drug treatments are given in a particular order using
 well-designed temporal pattern of consecutive treatments. In
greement with Kitano [1] and many key results in the field (e.g.
hen epidermal growth factor receptor inhibitors sensitized can-
er cells to subsequent DNA-damage by unmasking an apoptotic
athway in breast cancer see the work of [93] and the review of
uang and Kauffman in this issue) we strongly believe that sequen-
ial multi-target therapy will be the major mode of intervention in
ancer therapies of the future.
. Conclusions and perspectives
In conclusion, in this review we proposed that malignant trans-
ormation is a two-phase process, where an initial increase of
ystem plasticity is followed by a decrease of plasticity at late
tages of carcinogenesis of primary tumor cells or of metastatic cells
lready settled in their novel tissue environment. The increased
ystems-level plasticity of cancer initiating cells is characterized
y an increased
level of stochastic processes (noise);
network entropy;
“conformational noise” represented by intrinsically disordered
proteins and by low affinity interactions;
phenotypic plasticity;
cell heterogeneity;
physical deformability and
dissociation of network modules (Fig. 1).Our hypothesis would predict a decrease in all the above param-
ters in the late-phases of cancer development as opposed to the
arly phases described above. In late phase carcinogenesis theer Biology 23 (2013) 262– 269 267
increase of system rigidity may  be accompanied by an increased
hierarchy of regulatory processes.
The large structural changes of molecular networks during can-
cer development require a rather different targeting strategy in
early and late phase of carcinogenesis. Importantly, a more ordered
system is generally less controllable than a disordered one [25],
which warns that (A) therapeutic interventions of the early, more
plastic stage of carcinogenesis are more efficient than those against
late-stage tumors; (B) late-stage tumors should be attacked by
an entirely different strategy than early-stage tumors, see Fig. 1
and [26]. Besides other therapeutic modalities (such as surgery,
radiotherapy etc.) at the early phase of cancer development hitting
of central nodes of cancerous molecular networks (such as inter-
modular hubs being in the cross-roads of regulatory processes) may
become a winning strategy killing the very heterogeneous cancer
cell population. However, central hit-type pharmacological inter-
ventions may  become useless at a later stage of carcinogenesis. Late
stage primary tumors or the already metastasized cells in their new
tissue environment should be attacked by the more indirect means
of network influence strategy, such as by edgetic, multi-target, or
allo-network drugs see Fig. 1 and [26,79,80], since here not the
eradication of a large heterogeneity of tumor cells, but the shift
of the malignant cellular network to a less malignant state is the
desired action.
Regretfully, many in vitro test systems of anti-cancer drug can-
didates resemble to the plastic cellular systems of early stage cancer
development, while disease is usually detected in patients, when
it reached the late phase of development [94]. The application of
early stage-optimized anti-cancer drugs to late-stage patients may
be a reason of many failures in anti-cancer therapies. This situation
underlies the importance of systems- level studies of cancer cell
development and the network analysis of the data obtained.
Importantly, the initial increase and later decrease of system
plasticity during cancer development may  appear both at the level
of the network of individual cells and at the level of the network of
cell populations. Heterogeneous cancer cell populations may  har-
bor early- and late-stage tumor cells at the same time. Moreover,
cancer stem cells may  have the ability to change their “plasticity
phenotype” from that of early- to late-stage tumor cells and vice
versa. Therefore, multi-target, combinatorial or sequential thera-
pies using both central hit- and network influence-type drugs may
provide an even more useful anti-cancer therapeutic modality than
previously thought.
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